Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

One could try to reverse engineer their power calc

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154060
(Total Views: 537)
Posted On: 01/11/2021 4:06:20 PM
Posted By: kabonk
Re: havasu78 #72190
One could try to reverse engineer their power calculations and assumptions on the study, using a power calculator like here:

https://www2.ccrb.cuhk.edu.hk/stat/proportion/Casagrande.htm

Assuming 80% power used to estimate sample size, with one sided test (H0: P1=P2 vs. Ha: treatment with LL lowers mortality from no treatment / placebo; i.e. P2<P1), the study sample size is approximated by assuming P1=mortality with placebo at 30%, and P2=mortality with LL at 18%. (Gives N=378 sample size, close to 390). So, these might be close to the numbers estimated at trial start to get our sample size and trial powered properly.

When discussing stats, people haven't talked much about confidence intervals or the margin of error in estimating mortality rates in each group, but these are critical when calculating the difference in proportions (absolute difference in mortality in our trial), to prove that it does not include 0. i.e. we want our reduction in risk of death to be less 0%; so a 12% absolute reduction from 0.3 to 0.18 might have a 95%CI from -16% to -8%, which would be good. However if it's only from 0.23 to 0.2 difference in mortality with LL, that -3% might have a 95% CI from -8% to +2%, which is not significant (it could be 8% drop, but it could also be a 2% increase in risk from LL).

From this number, we can also get the number needed to treat to save one life. It is just 1/(P1-P2). If the difference is 12.5%, then we would need to treat 8 people to save one life. They reported this number recently for the UK IL-6 trial. Mortality in their controls was 35.8%; Tocilizumab had 28% and Sarilumab 22.2% death rate. Combined, the reduction was from 35.8% to 27.2%, or a relative reduction of 24%, and absolute of ~8.6%. The number needed to treat to save a life was thus around 12 patients.

https://www.dummies.com/education/math/statis...oportions/

A similar concept for comparing differnce in proportions is the risk ratio or related odds ratio, to prove that it does not include 1.0. i.e. we want our relative risk of death to be less than 1 when using LL, so .18/.30 is 0.6 (or a 40% relative reduction in mortality). The confidence interval of the risk ratio that will tell us if this is significant or not. If reduction is 0.6, with 95%CI from 0.3 to 0.9, then that would be great. If the reduction / RR is 0.8, with 95% CI from 0.3 to 1.3, then that would not be significant.

https://www.cureus.com/articles/39455-whats-t...ard-ratios

Stats are interesting, but I forget everything I may have learned and I'm sure I've mis-stated something above.





(0)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us